image credit: Unsplash

Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue

December 1, 2020

Via: BioSpace

Rafael Pharmaceuticals (Formerly known as Cornerstone Pharmaceuticals, Inc.), Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613®(devimistat) in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Sara’s Cure and Sarcoma Alliance for Research through Collaboration (SARC), Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States.

Read More on BioSpace